{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:51:34Z","timestamp":1787226694241,"version":"build-2736575974"},"reference-count":36,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Avon Mesothelioma Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"PREDICT-Meso Accelerator","award":["Cancer Research UK - Reference C57060\/A29372"],"award-info":[{"award-number":["Cancer Research UK - Reference C57060\/A29372"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,10,5]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Mesothelioma is a heterogeneous disease that can be challenging to monitor and prognosticate. ASSESS-meso is a multicentre, prospective, longitudinal observational cohort study of patients with mesothelioma. The primary aim is to describe different clinical phenotypes and investigate predictive and prognostic factors, including biomarkers from blood and pleural fluid. The secondary aim is to provide a resource for future trials and substudies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We aim to recruit 700 patients with a histological, cytological or clinicopathological diagnosis of mesothelioma, at any anatomical site (pleural, peritoneal, pericardial, etc). Longitudinal data will be collected, including clinical information, radiological investigations, blood tests and patient-reported outcome measures for breathlessness, chest pain and sweats. Preplanned analyses will use Cox proportional hazards method to evaluate factors associated with survival, linear and logistic regression models to investigate associations with symptoms, and analysis of variance modelling to explore changes in symptoms over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval has been granted by the Research Ethics Committee South West\u2014Central Bristol (17-SW-0019) and Health Research Authority (IRAS ID 220360). A study steering committee has been established and results will be published OpenAccess in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ISRCTN: 61861764.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-060850","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T10:00:58Z","timestamp":1668074458000},"page":"e060850","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-7060","authenticated-orcid":false,"given":"Ruairi J H","family":"Conway","sequence":"first","affiliation":[{"name":"Department of Medicine, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"},{"name":"Academic Respiratory Unit, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Symonds","sequence":"additional","affiliation":[{"name":"Academic Respiratory Unit, University of Bristol, Bristol, UK"},{"name":"Department of Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Walton","sequence":"additional","affiliation":[{"name":"Academic Respiratory Unit, University of Bristol, Bristol, UK"},{"name":"Department of Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Probets","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Comins","sequence":"additional","affiliation":[{"name":"Bristol Haematology and Oncology Centre, Bristol Royal Infirmary, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Stadon","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E","family":"Harvey","sequence":"additional","affiliation":[{"name":"Academic Respiratory Unit, University of Bristol, Bristol, UK"},{"name":"Department of Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G","family":"Blyth","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"},{"name":"Beatson Institute, Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick A","family":"Maskell","sequence":"additional","affiliation":[{"name":"Academic Respiratory Unit, University of Bristol, Bristol, UK"},{"name":"Department of Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C","family":"Bibby","sequence":"additional","affiliation":[{"name":"Academic Respiratory Unit, University of Bristol, Bristol, UK"},{"name":"Department of Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2025121602321663000_12.11.e060850.1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0063-2016"},{"key":"2025121602321663000_12.11.e060850.2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National lung cancer audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"key":"2025121602321663000_12.11.e060850.3","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2017-211416","article-title":"British thoracic Society guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"key":"2025121602321663000_12.11.e060850.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2025121602321663000_12.11.e060850.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2025121602321663000_12.11.e060850.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.04.024"},{"key":"2025121602321663000_12.11.e060850.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60418-9"},{"key":"2025121602321663000_12.11.e060850.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70149-8"},{"key":"2025121602321663000_12.11.e060850.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2014.09.056"},{"key":"2025121602321663000_12.11.e060850.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5535"},{"key":"2025121602321663000_12.11.e060850.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"2025121602321663000_12.11.e060850.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"2025121602321663000_12.11.e060850.13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025121602321663000_12.11.e060850.14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/lmt.15.32","article-title":"New directions in mesothelioma treatment","volume":"4","author":"Nowak","year":"2015","journal-title":"Lung Cancer Manag"},{"key":"2025121602321663000_12.11.e060850.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4"},{"key":"2025121602321663000_12.11.e060850.16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.cllc.2020.01.007","article-title":"Clinical trials eligibility of patients with malignant pleural mesothelioma: use of novel therapies and outcomes","volume":"21","author":"Lau","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2025121602321663000_12.11.e060850.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12904-017-0255-3","article-title":"Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study","volume":"16","author":"Bibby","year":"2017","journal-title":"BMC Palliat Care"},{"key":"2025121602321663000_12.11.e060850.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh059"},{"key":"2025121602321663000_12.11.e060850.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.12.013"},{"key":"2025121602321663000_12.11.e060850.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1066"},{"key":"2025121602321663000_12.11.e060850.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.10.010"},{"key":"2025121602321663000_12.11.e060850.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.022"},{"key":"2025121602321663000_12.11.e060850.23","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"2025121602321663000_12.11.e060850.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00006-8"},{"key":"2025121602321663000_12.11.e060850.25","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.305"},{"key":"2025121602321663000_12.11.e060850.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123798","article-title":"Defining the minimal important difference for the visual analogue scale assessing dyspnea in patients with malignant pleural effusions","volume":"10","author":"Mishra","year":"2015","journal-title":"PLoS One"},{"key":"2025121602321663000_12.11.e060850.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13665-016-0130-3","article-title":"Measurement of breathlessness in patients with malignant pleural effusions","volume":"5","author":"Mishra","year":"2016","journal-title":"Curr Pulmonol Rep"},{"key":"2025121602321663000_12.11.e060850.28","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jtho.2021.05.018","article-title":"Serum proteomics and plasma Fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases","volume":"16","author":"Tsim","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025121602321663000_12.11.e060850.29","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-674","article-title":"A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice","volume":"14","author":"Linch","year":"2014","journal-title":"BMC Cancer"},{"key":"2025121602321663000_12.11.e060850.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1477"},{"key":"2025121602321663000_12.11.e060850.31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5301\/jbm.5000229","article-title":"Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma","volume":"32","author":"Bonotti","year":"2017","journal-title":"Int J Biol Markers"},{"key":"2025121602321663000_12.11.e060850.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004145"},{"key":"2025121602321663000_12.11.e060850.33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br J Cancer"},{"key":"2025121602321663000_12.11.e060850.34","doi-asserted-by":"crossref","unstructured":"de Fonseka D , Arnold DT , Stadon L , et al . A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma. BMC Cancer 2018;18.doi:10.1186\/s12885-018-4113-3","DOI":"10.1186\/s12885-018-4113-3"},{"key":"2025121602321663000_12.11.e060850.35","doi-asserted-by":"crossref","first-page":"5805-13","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025121602321663000_12.11.e060850.36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2015.07.014","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma","volume":"90","author":"Yamagishi","year":"2015","journal-title":"Lung Cancer"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-060850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:32:26Z","timestamp":1765881146000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-060850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,10]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/bmjopen-2022-060850"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-060850","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}